Clinical Trials
Pembrolizumab Plus SBRT Does Not Improve Event-Free Survival in Unresected Stage I/II NSCLC
Jabbour et alJournal of clinical oncology : official journal of the American Society of Clinical Oncology

Stereotactic body radiotherapy (SBRT) represents the standard of care for patients with inoperable stage I or II non-small cell lung cancer (NSCLC). The randomized, double-blind, phase III KEYNOTE-867 trial (ClinicalTrials.gov identifier: NCT03924869) evaluated whether adding pembrolizumab to thoracic SBRT improved outcomes in adults with untreated, inoperable stage I or II (T1 to limited T3, N0, M0; AJCC 8th edition) NSCLC, or in patients who declined surgery.
A total of 448 participants were randomly assigned in a 1:1 ratio to receive thoracic SBRT to primary tumors for 2 weeks or less concomitantly with either pembrolizumab 200 mg (n = 227) or placebo (n = 221) administered once every 3 weeks for up to 17 cycles. The primary end point was event-free survival (EFS) assessed by blinded independent central review.
At the prespecified first interim analysis, with a data cutoff date of June 11, 2024, the median follow-up time from randomization was 20.6 months (range, 1.3 to 56.8). Median EFS was 31.2 months (95% CI, 22.5 to 39.1) in the pembrolizumab arm versus 28.3 months (95% CI, 19.8 to 33.1) in the placebo arm (hazard ratio, 0.92; 95% CI, 0.69 to 1.24; P = .2932).
Among participants who received at least one dose of study therapy, grade 3 to 5 treatment-related adverse events were documented in 20.4% (46/226) of participants receiving pembrolizumab compared with 3.7% (8/218) receiving placebo. Five treatment-related deaths occurred, all within the pembrolizumab group (2.2%). Due to the unfavorable benefit-risk assessment, the KEYNOTE-867 trial was halted early, and all study treatments were discontinued.
Key Takeaways
- The addition of pembrolizumab to stereotactic body radiotherapy did not improve event-free survival compared with stereotactic body radiotherapy plus placebo (median 31.2 vs 28.3 months; HR 0.92; 95% CI, 0.69 to 1.24; P = .2932).
- Grade 3 to 5 treatment-related adverse events occurred in 20.4% (46/226) of patients in the pembrolizumab arm compared with 3.7% (8/218) in the placebo arm, including five treatment-related deaths (2.2%) that occurred exclusively in the pembrolizumab group.
- Based on the unfavorable benefit-risk profile, the KEYNOTE-867 trial was stopped prematurely and all study treatment was discontinued.
Read the original sourceJournal of clinical oncology : official journal of the American Society of Clinical Oncology
